CAR-T Meeting 2022 | CAR-T therapy, a novel promising treatment option for chronic hepatitis B and HBV-associated HCC
There are currently no curative treatments for chronic hepatitis B and chronic hepatitis B virus (HBV)-associated hepatocellular carcinoma (HCC). In this video, Ulrike Protzer, MD, Technical University of Munich, Munich, Germany, comments on the potential of using chimeric antigen receptor T-cell (CAR-T) therapy to treat these conditions. Upon integration in hepatocytes, the hepatitis B viral genome produces surface proteins that can be targeted with a CAR-T construct that would kill the infected cells. This interview took place at the EBMT-EHA 4th European CAR T-cell Meeting which was held virtually in 2022.
Disclosures
Share holder and board member of SCG Cell Therapy.
Ad hoc scientific advisor for AbbVie, Arbutus, Gilead, GSK, Johnson & Johnson, Roche, Sanofi, Sobi, and Vaccitech.
